11 completed, 5 recruiting, 1 active not recruiting, 1 terminated. 9 Phase 1, 8 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 6, Recruiting 2, Terminated 1 |
| Phase 2 | 8 | Completed 5, Recruiting 2, Active not recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Nodal Marginal Zone Lymphoma: new trials by email Literature Review of Nodal Marginal Zone Lymphoma trials Research Report on Nodal Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Epcoritamab - Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Recruiting | Izidore Lossos, MD | 25 | 2025-10-13 | 2026-10-15 |
| Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma Nodal Marginal Zone Lymphoma | Recruiting | International Extranodal Lymphoma Study Group (IELSG) | 300 | 2024-04-11 | 2026-06-22 | |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CAR.k.28, Fludarabine, Cyclophosphamide - Mantle Cell Lymphoma, Follicular Lymphoma | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 20 | 2020-11-12 | 2026-01-20 |
| MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas Ibrutinib, Rituximab - Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma | Phase 2 | Active not recruiting | International Extranodal Lymphoma Study Group (IELSG) | 175 | 2019-09-27 | 2026-04-08 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration - Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma | Not applicable | Completed | Mayo Clinic | 29 | 2016-01-19 | 2019-11-15 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma rituximab - Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma | Phase 3 | Completed | Biocad | 174 | 2011-09-01 | 2017-11-06 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma Bortezomib, Rituximab, Cyclophosphamide - Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma | Phase 2 | Completed | Mayo Clinic | 21 | 2008-08-01 | 2019-04-16 |
| Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Laboratory Biomarker Analysis, Vorinostat - Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2005-09-01 | 2018-03-06 |
| Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis - Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 / Phase 2 | Completed | Mayo Clinic | 38 | 2004-10-01 | 2016-02-04 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma Laboratory Biomarker Analysis, Tipifarnib - Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2004-03-24 | 2020-04-13 |
| Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms Bortezomib, Alvocidib Hydrochloride, Pharmacological Study - Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 93 | 2004-03-01 | 2014-12-23 |
Lymphoma, B-Cell, Marginal Zone (18) · Lymphoma, Follicular (14) · Lymphoma, Mantle-Cell (13) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Lymphoma, Non-Hodgkin (10) · Waldenstrom Macroglobulinemia (9) · Burkitt Lymphoma (7) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, Large-Cell, Anaplastic (6) · Lymphoma, T-Cell (6) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (6) · Immunoblastic Lymphadenopathy (5) · Intraocular Lymphoma (5) · Leukemia, Hairy Cell (5) · Lymphoma, Large-Cell, Immunoblastic (5)
Hemic and Lymphatic Diseases (18) · Immune System Diseases (18) · Immunoproliferative Disorders (18) · Lymphatic Diseases (18) · Lymphoma, B-Cell (18) · Lymphoproliferative Disorders (18) · Neoplasms (18) · Neoplasms by Histologic Type (18) · Lymphoma (15) · Hematologic Diseases (11) · Chronic Disease (10) · Disease Attributes (10) · Leukemia (10) · Leukemia, B-Cell (10) · Leukemia, Lymphoid (10)
Rituximab (6) · Bendamustine Hydrochloride (2) · Bortezomib (2) · Cyclophosphamide (2) · Vorinostat (2) · ibrutinib (2) · ARQ531 (1) · Biopsy (1) · CT-P10 (1) · Dasatinib (1) · Dexamethasone (1) · Indium (1) · Lenalidomide (1) · MLN 8237 (1) · Magnetic Resonance Spectroscopy (1)
National Cancer Institute (NCI) (8) · Mayo Clinic (3) · International Extranodal Lymphoma Study Group (IELSG) (2) · Biocad (1) · City of Hope Medical Center (1) · Izidore Lossos, MD (1) · Schrödinger, Inc. (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (16) · France (3) · Italy (3) · India (2) · Poland (2) · Portugal (2) · Spain (2) · Switzerland (2) · Ukraine (2) · Argentina (1) · Armenia (1) · Belgium (1) · Canada (1) · Colombia (1) · Croatia (1)
Thomas Witzig (2) · Annarita Conconi, MD (1) · Catherine Thieblemont, MD (1) · Craig Reeder (1) · Davide Rossi, MD (1) · Frank G Basile, M.D. (1) · Geoffrey Shouse (1) · Izidore Lossos, MD (1) · John Gerecitano (1) · John Sarantopoulos (1) · Leslie Andritsos (1) · Leslie Popplewell (1) · Natalie Grover, MD (1) · Roman Ivanov, PhD,MD (1) · Steven Grant (1)
PMID 40550489, PMID 21300924, PMID 21725056, PMID 28314788, PMID 31617432
P30CA015083 (4), P30CA033572 (3), U01CA062505 (2), 2018 (1), N01CM00100 (1), N01CM17101 (1), N01CM62209 (1), P30CA008748 (1), P30CA016058 (1), P30CA076292 (1), P50CA097274 (1), R01CA193140 (1), R21CA110953 (1), U01CA069856 (1), U01CA076576 (1)